Docwire News

There is a troubling upward trend of heart arrhythmias and acute myocardial infarctions (AMIs), especially in young male prediabetic individuals, according to findings from a new study presented at the American Heart Association 2019 Scientific Sessions in Philadelphia.

The use of methamphetamine (meth) can cause severe heart failure (HF) but stopping use can significantly improve according to the findings of a new study presented at the American Heart Association 2019 Scientific Sessions in Philadelphia.

Dapagliflozin is an effective treatment for patients with heart failure with reduced ejection fraction (HFrEF) across all age groups, according to the findings of a study presented at the American Heart Association 2019 Scientific Sessions in Philadelphia.

Racial bias of ethnic minorities, specifically African Americans, factors into the decision-making process for approving patients with heart failure for heart transplants, according to the findings of two studies being presented at the American Heart Association’s Scientific Sessions 2019 in Philadelphia, PA.

Artificial intelligence can be used to accurately examine electrocardiogram (ECG) test results, according to the findings of two preliminary studies being presented at the American Heart Association’s Scientific Sessions 2019 in Philadelphia, PA.

The findings of a new study suggest that individuals who have survived heart attacks have an increased risk of developing cancer.

New study results presented at the American Heart Association 2019 Scientific Sessions in Philadelphia suggest that an invasive interventional approach for treating stable ischemic heart disease yields no reduction in risk when compared to a less invasive approach.

A study called the BETonMACE trial, which was presented at the American Heart Association’s Scientific Sessions 2019, tested the hypothesis that adding the use of apabetalone to standard of care therapies improves cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (T2DM) and low HDL-C after an acute coronary syndrome (ACS).

The findings of the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF) suggest that dapagliflozin is effective in the treatment of reduced ejection fraction (HFrEF) in patients with and without type 2 diabetes (T2D).

PRESIDENTIAL SESSION – Tuesday, 12:45 pm This year’s presidential session, with remarks by American Heart Association CEO Nancy Brown, will...